.png)
Resilience Announces Long-Term Financing of up to $825 Million to Accelerate CDMO Strategy
New Capital from Oak Hill Advisors to Drive Investment in Go-Forward Manufacturing Operations CINCINNATI--(BUSINESS WIRE)--National Resilience...
BLOG
Read on
%201.png)
Navigating the Evolving Landscape of Fill/Finish: Trends, Challenges, and What’s Ahead
A Q&A with Nithin Stephen As the pharmaceutical and biotech industries continue to innovate at a rapid pace, the demand for fill/finish capabilities...
Leveraging Partnerships to Achieve Cell Therapy Success
What impact can partnerships have in cell therapy commercialization success? Eytan Abraham at Resilience discusses the need for a modernized...
Master Cell Banks: Laying the Foundation to Final Product Success
Consider our top 5 FAQs when it comes to MCBs Master cell banks (MCBs) are a critical starting material that lay the foundation for the scale-up and...
Alachua Biomanufacturing Expansion Video
We are remaking the way medicines are made and that starts with our facilities. At our Alachua, Florida campus, Building G defines the future of our...
.png)
Resilience to Establish Biomanufacturing Partnership with AstraZeneca and Purchase Manufacturing Site
SAN DIEGO--National Resilience, Inc. (Resilience) and AstraZeneca PLC announced today that the companies will establish a long-term biomanufacturing...
Cell Therapy – What Does It Take To Become a Mainstream Option
While cell therapies are still a small segment of therapeutics, the landscape is rapidly changing — with over 1,000 ongoing clinical trials and...
On Demand Drug Substance Manufacturing and Drug Product Fill/Finish Solutions Presentation
Download this on demand presentation detailing our drug substance manufacturing and drug product fill/finish capabilities. Simplify your GENE to IND...
